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Abstract: The population based Steroid Profile (SP) ratio of testosterone 
(T) and epitestosterone (E) has been considered as a biomarker approach 
to detect testosterone abuse in '80s. The contemporary Antidoping 
Laboratories apply the World Antidoping Agency (WADA) Technical Document 
(TD) for Endogenous Androgenic Anabolic Steroids (EAAS) in the analysis 
of SP during their screening. The SP Athlete Biological Passport (ABP) 
adaptive model uses the concentrations of the total of free and 
glucuronide conjugated forms of six EAASs concentrations and ratios 
measured by GC/MS. In the Antidoping Lab Qatar (ADLQ), the routine LC/MS 
screening method was used to quantitatively estimate the sulfate 
conjugated EAAS in the same analytical run as for the rest qualitative 
analytes. Seven sulfate EAAS were quantified for a number of routine 
antidoping male and female urine samples during screening. 
Concentrations, statistical parameters and selected ratios for the 6 
EAAS, the 6 sulfate EAAS and 29 proposed ratios of concentrations from 
both EAAS and sulfate EAAS, which potentially used as SP ABP biomarkers, 
population reference limits and distributions have been estimated after 
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irrelevant for doping analysis. In addition, statistics of 
other markers present very high variation due to the use 
of T-S or E-S in the denominator, two compounds with 
high incidence of below LOQ concentrations. This 
drastically increases the variation of the presented ratios 
and the relevance of its statistics, particularly when these 
concentrations are even more suppressed, which is the 
reason for putting them in the denominator. If the author 
does not want to cut in the presented markers, at least 
the high variance due to analytical limitations should be 
discussed. 
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-The T-S and E-S concentrations and ratios biomarkers showed high variation, due to 
the existence of significant percentages of values below LOQ and LOD (Table 1). In 
relation to analytical variation based on LOQ, the reduction of variation in E-S and T-S 
determinations can be achieved in lowering the validated LOQ [32]. The variation of 
T-S and E-S biomarkers due to samples without measurable MS signals, will be more 
difficult to be reduced, since the current used MS technology is of high mass accuracy 
and sensitivity. The intra-individual athlete baseline or after doping application 
variation of EAAS-S has to be defined in clinical studies. The inter-athlete population 
variation will play an important role and it has to be determined and considered in a 
potential incorporation of EAAS-S biomarkers in the ABP steroidal module. 
15  Comment: 
The author prefers to leave the data with a small 
database, thereby referring to the use of established 
software and other papers with similar database sizes 
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of Solberg et al [1]. The correct sample size applied for 
most of the used markers. If the author does not want to 
increase the database size, this shortage should be 
discussed for ratios with T_S in denominator for women. 
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-In another criterion, the RefVal software generates error messages if the number of 
population samples is below the specification of International Federation of Clinical 
Chemistry (IFCC) [36, 37] related to the selected confidence interval of the study. In 
the data processing of the current study by RefVal, no such error messages were 
generated, consequently the numbers of female and male samples included in the 
current population are in compliance with both specifications. 
-The RefVal estimations of Tables 4, 5 and 6 were provided following compliance with 
the RefVal criterion of 1 / N < α, where N is the values in the male and female 
populations [41, 42].    
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- Quantitation of intact endogenous sulfate steroids in sports antidoping screening. 
- LC/MS sulfates endogenous steroids for WADA Athlete Biological Passport. 
- Ratios from sulfate and free-glucuronide concentrations of athlete population. 
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The population based Steroid Profile (SP) ratio of testosterone (T) and epitestosterone (E) has 
been considered as a biomarker approach to detect testosterone abuse in ‘80s. The contemporary 
Antidoping Laboratories apply the World Antidoping Agency (WADA) Technical Document 
(TD) for Endogenous Androgenic Anabolic Steroids (EAAS) in the analysis of SP during their 
screening. The SP Athlete Biological Passport (ABP) adaptive model uses the concentrations of 
the total of free and glucuronide conjugated forms of six EAASs concentrations and ratios 
measured by GC/MS. In the Antidoping Lab Qatar (ADLQ), the routine LC/MS screening 
method was used to quantitatively estimate the sulfate conjugated EAAS in the same analytical 
run as for the rest qualitative analytes. Seven sulfate EAAS were quantified for a number of 
routine antidoping male and female urine samples during screening. Concentrations, statistical 
parameters and selected ratios for the 6 EAAS, the 6 sulfate EAAS and 29 proposed ratios of 
concentrations from both EAAS and sulfate EAAS, which potentially used as SP ABP 
biomarkers, population reference limits and distributions have been estimated after the 
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The sports anti-doping movement is led worldwide by the World Anti-Doping Agency 
(WADA). WADA publishes every year the Prohibited List Substance, which is the definition of 
doping [1]. The Prohibited List incorporates several pharmacological classes and examples of 
drugs as endogenous or synthetic substances. Anabolic Androgenic Steroids (AAS) are the most 
frequently reported prohibited substances according to the several years’ statistics that can be 
retrieved in the official WADA site report [2]. Externally administrated testosterone (T) and its 
metabolically related substances, the synthetic forms of the Endogenous AAS (EAAS), are often 
abused by the athletes in order to avoid urinary detection, because conventional mass 
spectrometry (MS) the mass spectra of the endogenously produced and the exogenous introduced 
T are the same and cannot be distinguished, unless Isotope Ratio Mass Spectrometry (IRMS) is 
used [3,4]. In 1982, the implementation of a population based steroid profile (SP) ratio for T and 
its epimer epitestosterone (E) has been considered as a biomarker to detect testosterone abuse 
[5]. After 1982, the SP was enriched by adding more T metabolites, and a plethora of studies 
have been published to describe the stability of SP, the population reference ranges and 
conditions that SP changes [3,4]. The anti-doping laboratories accredited by WADA apply the 
Technical Document for EAAS (TD2018EAAS) [6] in the analysis and evaluation of the SP 
during their Initial Testing Procedure (ITP). The current SP evaluation is based on individual 
athlete and athletes’ population reference ranges using the Bayesian statistical model developed 
by Sottas [7-9], which is based on the model used for the blood Athlete Biological Passport 
(ABP) [10]. The steroidal module of the ABP uses the concentrations of the following EAAS, 
which are extracted from urine and include total of the free and glucuronide conjugated forms: 
androsterone (A), etiocholanolone (Etio), 5α-androstane-3α,17β-diol (5αAdiol), 5β-androstane-
3α,17β-diol (5βAdiol), T, E and ratios between them T/E, A/T, A/Etio, 5αAdiol/5βAdiol. All 
EAAS are analyzed by gas chromatography/mass spectrometry (GC/MS) [6, 11-13]. 
The current SP ABP system has been originated from various studies made in the past. In 
1976, Harris et al. proposed models of time series data obtained from an individual for clinical 
purposes [14]. The basis of the time series data evaluation is that each individual has a biological 
average about which the parameter concentration varies as a function of time. In the anti-doping 
literature, several reference ranges and SP population statistics have been published, e.g. [15-17] 
and a thorough review has been published by Ayotte et al. [4]. Factors that affect the SP divided 
into endogenous and exogenous factors and these factors have been reviewed and identified such 
as, confounding factors as alcohol, masking agents, exogenous steroids [3, 6, 18], genetic 
polymorphisms [19] or urine dilution [20]. In order to enhance the detectability of T and its 
prohormones abuse, SP improvement with additional biomarkers has been proposed [17]. The 
application of ultra-high performance liquid chromatography (UHPLC) on the measurements of 
blood concentrations of T, its major metabolites, and precursors could be a complementary 
information of SP for the EAAS [21]. The detection of four T metabolites extracted after urine 
alkaline treatment has been developed after a single dose administration of T in a gel formulation 
and prohormone forms [22]. 
The complementary SP of T and sulfate metabolites has been the subject of several studies. 






































































sulfate, glucuronide). Bowers et al. developed a method for detecting directly the sulfate and 
glucuronide conjugates of urine steroid metabolites by using HPLC/MS/MS [24]. A different 
approach from Schänzer and coworkers has developed by analyzing urine using a sequential 
extraction of free with glucuronide and sulfate conjugates in two steps and the examination of 
population distribution [25]. A steroidomic approach for biomarkers discovery has been 
developed with the participation of the WADA accredited laboratory of Lausanne (Switzerland), 
which concluded the monitoring of both glucuronide and sulfate steroid conjugates as 
biomarkers and included them in the SP ABP [26]. Another study from the same group described 
an investigation of the steroid metabolism after transdermal and oral T administration and 
concluded that sulfo-conjugated steroids might provide helpful screening information for 
individuals with homozygous UGT2B17 deletion, while the hydroxy-glucuroconjugated EAAS 
could enhance the detection window of oral T undecanoate abuse [27]. The use of the sulfate 
fraction biomarkers has been also supported by other studies. Schulze and coworkers found that 
after a dose of T enanthate, the T sulfate (T-S) levels were markedly decreased to negligible 
levels because exogenous T is not sulfated at all [28]. In another study, also Schulze and 
coworkers concluded that after administration of exogenous T (T enanthate), the urinary 
excretion rate of dehydroepiandrosterone sulfate (DHEA-S) and T-S decreased approximately by 
50% and 80% respectively [29]. Finally, a study conducted in the WADA accredited laboratory 
in Cologne (Germany), found that the retrospective detection of T misuse can be performed by 
monitoring the epiandrosterone sulfate (epiA-S) [30]. In a recent study, 14 endogenous steroid 
sulfates were measured to improve the detection capabilities of oral T administration [31]. 
WADA accredited laboratories estimate quantitatively the SP of EAAS and their ratios 
results are reported electronically during routine ITP [6]. The analysis is conducted either by 
GC/MS or gas chromatography/tandem mass spectrometry (GC/MSMS) in an extracted and 
hydrolyzed urine to cleavage only the glucuronidate conjugations moiety, while in this condition 
the Phase II conjugated EAAS-S remain intact and are not measured. A recent study by ADLQ 
group has shown the capability of the routine LC/MS ITP method to quantitatively estimate the 
EAAS-S in the same analytical run as for the rest qualitative analytes [32]. In the current study, 
seven EAAS-S related to T metabolism, selected according to the existing literature, were 
quantified in a set of routine anti-doping samples. Female and male elite athlete population 
statistical parameters, reference limits, distributions of nominal concentrations and ratios have 
been estimated by combining GC/MSMS [11] analysis for the EAAS and LC/MS analysis [32] 
for the EAAS-S. The EAAS and EAAS-S concentrations and the ratios between them were 
considered as potential biomarkers to enhance specificity and sensitivity of the urinary SP 
applied in sports antidoping through the WADA ABP system. For this purpose, athletes’ samples 
with EAAS and EAAS-S concentrations measured below the established from analytical method 
validation limit of quantitation (LOQ) were not excluded from the current database, as this 







































































2. Materials and Methods 
2.1. Samples 
 
Routine Samples received at ADLQ within a period of eight months has been selected and 
analyzed by GC/MS and LC/MS as part of ITP, as described in sections 2.3 and 2.4. No 
additional analysis was conducted for the current study other than the mandatory ITP. There is an 
extensive variability of the ethnicities of the athletes, whose samples were analyzed, because of 
the geographical diversity of the testing authorities collaborating with ADLQ. As all anti-doping 
samples are always received as anonymized, the athletes’ gender was the only information 
available for the samples used in this study. These anti-doping samples were classified as non-
research samples according to the paragraph 6.3 of the World Anti-Doping Code [33]. In order to 
create population statistics originated from samples negative for doping substances, the 
following exclusion criteria were used: samples officially reported to contain any kind of 
substances and confounding factors and samples with bacteria urine degradation signs according 
to TD2018EAAS[6] were not included in the study. Moreover, after the statistical analysis 
described in section 2.6. herein, samples characterized as outliers were also removed before 
applying the population statistics.  
All samples had been stored frozen in -20
o
C prior analysis. The sample preparation had been 
performed one or two days after the delivery of the samples at ADLQ. The specific gravity and 
pH measurements were conducted before ITP analysis by using a digital refractometer Atago 
3464 and a Thermo Scientific Orion Star A111 pH-meter respectively. 
 
2.2 Materials and reagents 
 
2.2.1. Chemicals  
 
The following chemicals were purchased from Sigma Aldrich (Darmstadt, Germany): 
sodium hydrogen bicarbonate (NaHCO3), sodium carbonate (Na2CO3), di-potassium hydrogen 
phosphate trihydrate (K2HPO4×3H2O), potassium dihydrogen phosphate (KH2PO4), acetonitrile 
and methanol (HPLC grade). β-Glucuronidase from Escherichia Coli (E. coli) was purchased 
from Roche Diagnostics (Mannheim, Germany). Ethyl acetate, diethyl ether, N-methyl-N-
trimethylsily-trifluoroacetamide (MSTFA) and 2-Propanethiol were supplied from Merck 
(Darmstadt, Germany). Formic acid (HCOOH) and 5 M ammonium formate (HCOONH4) were 
obtained from Agilent Technology (Santa Clara, United States). Ammonium Iodide (NH4I) was 
purchased from Acros Organics (Geel, Belgium). 
 
 
2.2.2. Reference standards 
 
The following reference standards and deuterated internal standards were used for LC/MS 
analysis: androsterone sulfate (A-S), etiocholanolone sulfate (Etio-S), T-S, epitestosterone 
sulfate (E-S), DHEA-S, 5α-Dihydrotestosterone Sulfate (5α-DHT-S), androsterone sulfate-d4 






































































purchased from National Measurement Institute (NMI, Pymble, Australia). epiA-S and 
epiandrosterone sulfate-d5 (epiAS-d5) were obtained from Toronto Research Chemicals (TRC, 
Toronto, Canada). Dehydroepiandrosterone-d5-3-sulfate (DHEAS-d5) was obtained from 
Cerilliant (Texas, United States). The deuterated internal standards for qualitative screening were 
mefruside-d3, morphine 3-β-D-glycuronide-d3 and phendimetrazine-d3 and acquired from TRC 
(Toronto, Canada). 
The following reference standards and deuterated internal standards were used for GC/MS 
analysis: A, Etio, T, E, 5αAdiol, 5βAdiol, etiocholanolone-d5 (Etio-d5), androsterone-β-
glucuronic acid-d4 (AGlu-d4), 5β-androstane-3α,17β-diol-d5 (5βAdiol- d5), testosterone-d3 (T- 
d3) , epitestosterone -d3 (E- d3) were purchased from National Measurement Institute (NMI, 
Pymble, Australia). 
Stock standard solutions were prepared in methanol for each of the examined analytes. The 
working standard solutions was prepared in methanol by appropriate dilutions of the respective 
stock solutions. All stock and working standard solutions were stored at -20 ° C in dark vials. 
The steroid profile for EAAS and EAAS-S were prepared in a different working solutions. 
Seven-points calibration curves were prepared for each of EAAS-S steroid spiked in a pool 
clean-up female child urine: T-S, E-S, 5α-DHT-S: 0.5-100 ng/mL, epiA-S: 2.5-500 ng/mL, A-S, 
Etio-S, and DHEA-S: 10-2000 ng/mL. The internal standard (ISTD) mixture solution of 5α-
DHTS-d3/AS-d4/ TS-d3/ epiAS-d5/ DHEAS-d5 was prepared at the concentrations of 
1.0/20.0/5.0/10.0/10.0 μg/mL, respectively. 
The steroid profile calibration curves of EAAS were prepared using the same pool of female 
child urine at different concentration levels, where the exact concentrations depended on each 
steroid: T, E: 1-200 ng/mL, 5αAdiol, 5βAdiol: 4-800 ng/mL, A, and Etio: 100-8000 ng/mL. The 
ISTD mixture solution of Etio-d5/ AGlu-d4/ T-d3/ E-d3/ 5βAdiol- d5 was prepared at the 
concentrations of 50.0/50.2/1.60/0.40/2.0 μg/mL, respectively. 
 
2.3. GC/MS analysis 
 
2.3.1. Sample preparation 
 
A 2.5 mL urine sample were added 25 μL of ISTD followed by enzymatic hydrolysis using 1 
mL of phosphate buffer (pH=7) and 50 μL of β-glucuronidase enzyme from E. coli for 1.5 h at 
50° C. After hydrolysis, the pH of urine sample was adjusted to 9-10 using solid mixture of 
sodium hydrogen bicarbonate and sodium carbonate (10:1) (w/w) followed by liquid-liquid 
extraction (LLE) using 5 mL diethyl ether. Then, anhydrous sodium sulfate was added to all 
samples and shaken for 20 min. After centrifugation, the organic layer was separated from 
aqueous phase by freezing the samples at –80° C then evaporated under nitrogen flow at 50° C. 
The residues were derivatized with 50 μL of MSTFA/NH4I/2‐Propanthiol (1000:4:8) and 
incubated in 100° C for 60 min. Finally, the samples were transferred to the relevant vials and a 2 










































































GC/MS analysis was achieved by using an Agilent GC 7890 coupled with an Agilent 7000 
QQQ MS equipped with an Agilent 7693 auto sampler (Agilent Technologies, Santa Clara, CA, 
USA). The GC separation was performed in a SGE BPX5 column (30 m length, 0.250 mm i.d., 
0.1 µm film thickness, Trajan Scientific Ringwood, Australia). GC oven temperature program 
was the following: an initial oven temperature was 160° C, ramped at 10° C /min to 200° C, then 
ramped at 2° C /min to 220° C, ramped at 6 ° C /min to 292° C, 50° C /min increased to 310° C 
and held for 3 min before cooling-down to initial conditions. The injection volume was 2 μL in a 
split ratio of 1:10. The total analysis time was 28.4 min with a solvent delay of 2.60 min. The 
collision cell parameter for helium quench gas flow was 2.25 mL/min and the nitrogen gas flow 
was 1.5 mL/min. Additionally, helium carrier gas was set at flow of 1.1 mL/min. The front inlet 
and the interface transfer line heater temperatures were maintained at 280° C. The mass 
spectrometer was operated with the electron impact (EI) mode under the following setting: ion 
source temperature was 230° C, electron energy was 70 eV and quadrupole temperature was set 
to 150° C. The data acquisition was performed in multiple reaction monitoring (MRM) mode 
with the collision energy optimized from 5 eV and 35 eV depending on the analyzed compounds. 
The transitions used for quantification were m/z 432.3→209 for T and E, m/z 434.3→ 239.1 for 
A and Etio, and m/z 256.2→ 185.2 for 5αAdiol and 5βAdiol. MassHunter Software (Agilent, 
Santa Clara, CA, USA) was used for acquisition and data analysis.  
 
2.4. LC/MS analysis 
 
2.4.1. Sample preparation 
  
The ISTD mixture and calibration curves in this study were adjusted by including epiA-S 
calibrartion, epiAS -d5 and DHEAS-d5 ISTDs and altering the calibration ranges of T-S, E-S and 
5α-DHT-S. 5 ml of urine aliquots were added 50 μL of ISTDs. The enzymatic hydrolysis were 
applied for all samples by adding 100 μL of β -Glucuronidase from E. coli, 1 mL phosphate 
buffer at pH 7 (Na2HPO4 0.8 M and NaH2PO4 0.4 M) and incubated at 50° C for 1.5 hour. After 
cooling the samples, the pH was adjusted to 9–10 by addition of solid mixture NaHCO3:Na2CO3 
(10:1) (w/w). LLE was performed by the addition of 5 mL ethyl acetate and anhydrous sodium 
sulfate. The samples were shaken for 20 min and centrifuged at 3000 rpm for 12 min. The 
organic layer was separated from the aqueous phase by frozen samples using ethanol at -80° C. 
Subsequently, the organic phase of each sample was transferred to the relevant conical tube and 
200 μL of 3 M acetic acid in ethyl acetate were added. The organic layer was evaporated up to 
dry under stream of nitrogen at 40° C. The residue was dissolved in 200 μL of reconstitution 
solvent (mobile phase A/B 80:20; v/v). Finally, the reconstituted extract were mixed with 20 μL 




The LC/MS analysis [32] was performed using a Dionex UHPLC system (Thermo Scientific, 






































































(Thermo Scientific, Bremen, Germany). The chromatographic separation was performed using a 
Zorbax Eclipse Plus C18 column (100 × 2.1 mm i.d., 1.8 µm particle size; Agilent Technologies, 
Santa Clara, CA, USA). The column oven and the auto-sampler temperatures were set at 30° C 
and 7° C, respectively. Water containing 5 mM HCOONH4 and 0.02% (v/v) HCOOH (solvent 
A) and mixture of acetonitrile/water (90:10 v/v) containing 5 mM HCOONH4 and 0.02% formic 
acid (solvent B) were used as mobile phase solvents. A gradient elution program was set at a 
constant flow rate of 0.2 mL/min. The gradient organic solvent (B) started with 5% for 1 min, 
changed to 32% in 2.5 min, then remained isocratic for 13 min, and changed to 100% within 8 
min, held for 2.5 min before returning to the initial 5% within 1 min. The analysis run time was 
28 min and the post-run equilibrium time was 4 min. The injection volume was 5 μL. 
The mass spectrometer was operated in positive–negative polarity switching mode and 
equipped with a heated electrospray ionization (HESI) source with the following settings: 
capillary temperature 300°C, the heater temperature  30°C, S-lens radio frequency (RF) level  55, 
and sheath gas, ion sweep gas, and auxiliary gas flow rates  set at 40, 10, and 1 arbitrary units, 
respectively. Nitrogen was used as sheath, ion sweep and auxiliary gas. The ion spray voltage 
was set to 4000 kV for the positive ionization and 3800 kV for the negative ionization. All 
EAAS-S were detected in full scan (FS) negative ionization mode. The settings of the FS 
acquisition mode were as follow: scan range m/z from 100-1000 at 17500 resolving power, 
automatic gain control (AGC) target was set at 10
6
 and duty cycle was 100 ms. The deprotonated 
molecules [M-H]
–
 were used for the quantification of the EAAS-S: m/z 369.1585 for T-S, E-S, 
DHEA-S, m/z 369.1741 for 5α-DHT-S, epiA-S, A-S and Etio-S, m/z 373.1992 for AS-d4, m/z 
370.1773 for TS-d3, m/z 372.1899 for DHEAS-d5, m/z 374.2055 for epiAS-d5 and m/z 372.1929 
for 5α-DHTS-d3. Thermo Xcalibur and LCquan
TM 
version 3.0 (Thermo Scientific, Bremen, 
Germany) were used for acquisition and data analysis, respectively. 
 
 
2.5. Data Processing 
Identification and integration of the analytes obtained by standard integrated software were 
checked manually, as routine ITP process implemented at ADLQ. ITP quality control (QC) 
samples spiked with EAAS and EAAS-S from reference solutions were included in the study. 
Samples with concentrations above the highest concentration level of the calibrations’ curves, 
were re-analyzed with an appropriate dilution. Samples with concentrations below LOQ and 
limit of detection (LOD) were included in the study for the sake of the statistical processing [34] 
and to create the real and unbiased image of the athlete population for all those new SP markers. 
For the latter samples, the steroid concentration considered for the study was the one calculated 
from the instrument’s calibration curve. 
The quantitative analysis of EAAS was performed using calibration curves of seven 
concentration levels which included one spiked QC sample and two low and high steroid profile 
for quality control purposes and acceptance criteria. The concentration of EAAS were calculated 
based on the peak height ratios of compounds versus corresponding deuterated internal 
standards. The correlation coefficient of each calibration curves were assessed for each steroid to 
be greater than 0.990. The calibration curves of EAAS-S comprised seven concentration levels 






































































of EAAS-S were built based on the peak area ratios of T-S and E-S to T-S d3, A-S and Etio-S to 
A-S d4, DHEA-S to DHEAS-d5, α5-DHT-S to α5-DHTS-d3 and epiA-S to epiAS-d5. Instrument 
tuning and calibration and analytes’ method calibration curves were performed at every 
analytical batch. 
The SP concentrations of EAAS and EAAS-S where normalized by the application of the 
SG-adjustment method used by WADA based on the Levine-Fahy equation [6, 20]: 
     
  
   
     
  
   
   
       
          
  
The instrument measured concentration C in ng/mL and was adjusted to a population reference 
SG value of 1.020 [5]. 
 
2.6. Statistical analysis 
Data analysis was performed by SPSS version 25.0 (IBM SPSS Statistics for Windows, 
Version 25.0, IBM Corporation, Armonk, NY, USA) software package. Data distribution was 
tested using the Kolmogorov-Smirnov (K-S) normality test, applied for all steroids and 
corresponding ratios. The same K-S test was applied after logarithmic transformation of the data. 
Significance was set at p < 0.05 level and all tests were 2-tailed with 95% confidence intervals 
(CI). Outlier detection occurred with the Horn`s algorithm applying a Tukey Fence Factor of 2.1 
[35] using RefVaL program [36, 37]. The outliers were removed from the statistics. 
Determination of upper reference limits (RL) was performed using RefVaL including 97.5%, 
99% and 99.5% fractiles each calculated within a 95% CI. Furthermore, the non-parametric 
approach of applying twice ‘far outside’ value, defined as ‘2 × [75
th
 percentile + (3 × 
interquartile range)]’, was adopted to determine a threshold value [38, 39]. The minimum 
number of population samples of the study were in compliance with RefVal specifications. 
Pearson correlation coefficients (rp) were calculated to determine the strength of the relationship 







































































3. Results and Discussion 
 
Two separate databases, 780 males’ samples and 373 females’ samples, were created with 
EAAS and EAAS-S concentrations (ng/mL) and selected concentration ratios. The GC/MS 
EAAS [11] and LC/MS EAAS-S [32] analytical batches quality control comprised criteria in 
compliance with the specifications of WADA Technical Document [6] for EAAS. More 
specifically, the hydrolysis efficiency was controlled to all samples by isotopically labeled Phase 
II glucuronide conjugated ISTD for EAAS. The deuterated morphine glucuronide was used as an 
ISTD in EAAS-S aliquots for the non-sulfate conjugates glucuronidated analytes. The 
derivatization efficiency was checked in EAAS analysis in all samples by monitoring the mono-
trimethylsilyl derivative of A. The extraction efficiency and matrix effects were checked by the 
deuterated ISTD in both EAAS and EAAS-S. The microbial degradation signs were monitored in 
EAAS aliquots by the urine degradation products [6]. Finally, the confounding factors that may 
affect the SP in EAAS analysis were also monitored according to TD2018EAAS [6]. 
The EAAS concentrations of the databases in this study were those officially reported for the 
WADA ABP, except for the concentrations that were estimated below LOQ. The specification of 
WADA [6] requests that the concentrations of EAAS below LOQ to be reported as “-1” and 
below LOD as “-2”. This specification has been introduced in order to harmonize the reporting 
concentrations below LOQ among all WADA Accredited laboratories. The low concentration SP 
reporting harmonization is mandatory for the longitudinal intra-athlete of ABP module 
evaluation. The current study presents the unbiased population data as a monitoring concept 
rather than data to be introduced for ABP module evaluation according to the official WADA 
reporting specifications. Consequently, the “-1” and “-2” annotations of the officially reported 
concentrations were replaced by the concentrations calculated by the instrument’s calibration 
curves per steroid, despite the fact that those concentrations were lower than the lowest 
concentration level of the calibration curve. The original EAAS officially reported parameters 
did not comprise any “-2”; i.e. all EAAS, in all male and female samples of this study, the MS 
signal was always monitored and converted to a concentration level. The same practice applied 
for EAAS was followed to the concentrations of EAAS-S. However, 6.9% (54 out of 780) of 
samples for males and 21% (79 out of 373) of samples for females had no T-S MS signal, as they 
contained no measurable signal of T-S. Similarly, for E-S, one sample for males and three 
samples for females contained no measurable signal. The zero numerical values of those samples 
with no MS signal for T-S and E-S were replaced with 0.005 ng/mL for the sake of statistical 
processing, as referenced in a previous anti-doping population study [39]. Those values were not 
adjusted for SG, as for the rest of the concentrations. A minimum number of 300 samples is 
required to create meaningful results, as it has been considered in the study of the Cologne 
Laboratory [15]. In another criterion, the RefVal software generates error messages if the 
number of population samples is below the specification of International Federation of Clinical 
Chemistry (IFCC) [36, 37] related to the selected confidence interval of the study. In the data 
processing of the current study by RefVal, no such error messages were generated, consequently 






































































with both specifications. All data transformations described in this paragraph were applied 
before any statistical processing. 
The K-S test results revealed that none of the parameters set in both populations could be 
considered as normal (Gaussian) distributed, not even after logarithmic transformation. 5α-DHT-
S was removed from the database, since its signal was not detected in the vast majority of male 
and female samples. 
In Table 1, EAAS and EAAS-S statistics in male (n=780) and female (n=373) populations, 
including the inter-quartile range (IQ1–IQ3), median, mean, minimum, maximum concentration, 
the percentage of measurements below LOD and below LOQ and the number of outliers, are 
presented. Four steroids, A, Etio, T, E were included in both populations, for EAAS and for 
EAAS-S. For all four steroids in both males and females, lower mean EAAS-S concentrations 
were measured compared to mean EAAS. The 5αAdiol and 5βAdiol of EAAS were not included 
in EAAS-S, because of the lack of reference materials and the existence of two hydroxyl-groups 
in each molecule, which creates multiple Phase II conjugates. On the other hand, in EAAS-S 
populations, DHEA-S [29] and epiA-S [30] were included, since the former is suppressed, and 
the latter is increased with T administration. The concentrations of the EAAS are higher in males 
compared to females, as already reported in previous studies. The mean concentrations of EAAS 
are similar to the previous studies [15, 16] in both the male and female populations. The mean 
concentrations of EAAS-S in males are more than 50 % higher than in females, except the Etio-
S. The median values of T-S, A-S and DHEA-S are higher than the previous study done by Kuk 
et al. [24]. In the referred article, the EAAS-S population concentrations after ITP analysis were 
not published and therefore cannot be compared with our findings. 
Steroid ratios are applied metric in anti-doping screening of athletes [3, 6, 17]. Based on the 
databases (Table 1), a number of ratios between EAAS and EAAS-S concentrations were created 
and presented in Tables 2 and 3 for males and females respectively, together with the inter-
quartile range (IQ1–IQ3), median, mean, minimum, maximum concentration and the number of 
outliers per ratio. The WADA Technical Document [6], except the SP concentration markers 
presented also in Table 1, incorporates additional markers as EAAS ratios, which are referred 
herein as ratios 1-6 in Table 2. The ratio 1 has been calculated following the specifications of 
TD2018EAAS [6]; i.e. EAAS T/E ratios per sample were determined from the ratios of the 
chromatographic peak heights and the respective response factors, as determined by MassHunter 
software. However, all other ratios in the current study, were determined as the concentration 
ratios of EAAS and EAAS-S. Consequently, for consistency between T/E and the rest 
determined ratios in this study, the T/E ratio 2 was based on concentrations. The numerical 
values of T/E ratios 1 and 2 per sample were similar with a Pearson Correlation equal to 0.996. 
In the current study, mean and median of T/E in male population were calculated 1.2 and 0.96 
respectively (Table 2), while previous researchers [15, 16, 17] calculated the same statistics as 
1.6 and 1.4 respectively. The slightly lower values calculated in the current study could be 
explained by the fact that ADLQ analyzed samples mainly originated from Asian populations, 
where the homozygous UGT2B17 deletion genotype [28] is more common compared to the 
Caucasian population. For female population, the mean of T/E is lower than male population as 
expected and lower than the ratios described in the previous study [16]. No outliers were 






































































higher than in earlier studies [16]. For females, the mean A/T is four times higher than for males, 
due to the lower concentration of T in females. Mean values for A/Etio in male population is 
similar to previous studies [15, 16, 17, 23] after the removal of three outliers. For female 
population, the mean A/Etio is similar to the value found in pervious study [16] and one outlier 
was removed. For both populations, similar mean values for ratios 5αAdiol/5βAdiol and 
5αAdiol/E were found between the present study and previous ones [16, 17]. 
The ratios 7-37, either they have been proposed from literature, like ratio 27 [23], or they 
have been presented herein, following the concept that after T or prohormones administration the 
numerator is increased, and the denominator remains either unaffected or even suppressed, 
because the exogenous applied steroid is not converted to sulfate EAAS-S. The only exception to 
this concept is the ratio 26 for T-S/E-S, which was included in the database as comparable 
biomarker to the classical ratio T/E [5]. More specifically, the ratios 8 to 16 were introduced with 
T-S in denominator, following data from previous studies. This data shows that exogenous T 
probably is not sulfated, 95% of TS is originated from testis and it is decreased after T 
administration due to suppression of the luteinizing hormone (LH) secretion [28]. Additional 
data from T administration studies, comprising different subject genotypes, need to be created 
for the ratios 8 to 16. Population data for ratios 8-16 did not incorporate the samples with TS 
concentrations replaced by 0.005 ng/mL. Similarly, the ratios 17-25 and 29-37, having E-S and 
DHEA-S as denominators, would be expected to increase after T abuse. In a previous study [23], 
E-S was introduced in the denominator of the T/E (ratios 1, 2 herein), also included in the current 
database (ratio 27 herein), in order to improve marker discrimination between physiologically or 
pharmacologically abnormal T/E. The same conclusion has also been created from another 
recent study [31] for E-S. The suppression of E and LH, most probably of E-S as well, is not 
systematic. Depended on the individual metabolism, the E-S is potentially a valid SP parameter, 
especially in contributing in ratios in denominator position. Moreover, E-S measured above LOD 
except in a very few samples. Similarly, the DHEA-S is suppressed following T administration 
[28]. The ratio 27 has been included in our study as it has been proposed in a previous study [23] 
based only on GC/MS analysis. The ratios 7 and 28 have been included following the SP ABP 
for E, where E is used as denominator in ratios. In general, very few outliers are listed in Tables 
2 and 3 and the samples corresponding to the outliers were removed from the ratio calculation. 
The ratios of male samples 1, 2, 17 and 27 composed by T as numerator showed bimodal 
distributions [3], similarly to T concentrations of the current study. The male ratio 29, T/DHEA-
S did not show a bimodal distribution, probably due to the fact that the numerical values are 
distributed in the area of 0.2 (mean). T/DHEA-S is probably a sensitive biomarker of the T 
abuse. 
In Table 4, the 97.5% (α=2.5%), 99% (α=1%), 99.5% (α=0.5%) reference limits (RL) and the 
respective 95% confidence intervals (CI) of all compounds’ concentrations for male and female 
populations are presented. In Tables 5 and 6, the same statistical parameters listed in Table 4 
have been evaluated for the ratios presented in Tables 2 and 3, for males and females 
respectively. The data in Table 4 showed similar 97.5% reference limits for EAAS in both male 
and female populations, to those reported in a previous study [17]. Similarly 97.5% RL values 
for of  T/E , A/Etio and 5αAdiol/5βAdiol in both populations were found comparable with the 






































































Annex L [40], the 99% reference range, from a lower limit of 0.5% to an upper limit of 99.5%, 
for the normal physiological biomarkers, is applied for the ABP. The RefVal estimations of 
Tables 4, 5 and 6 were provided following compliance with the RefVal criterion of 1 / N < α, 
where N is the values in the male and female populations [41, 42].    
In Table 7, the calculated tentative upper limit of the monitored steroids concentrations and 
ratios in male and female populations are presented. Moreover, for each parameter of Table 7, 
the number of samples exceeding the double of far outside value per figure, is presented. The 
ratios 8-16 statistics provided large numerical values due to the fact that T-S concentrations in 
the denominators of the ratios were low in a significant part of the athlete population. This 
condition resulted in high ‘far outside’ x 2 numerical figures and additionally, a large number of 
samples with ratios exceeding that upper limit. It can be concluded that the ratios 8-16 could be 
applied only to athletes with higher T-S concentrations after collecting data from T 
administration studies. 
The T-S and E-S concentrations and ratios biomarkers showed high variation, due to the 
existence of significant percentages of values below LOQ and LOD (Table 1). In relation to 
analytical variation based on LOQ, the reduction of variation in E-S and T-S determinations can 
be achieved in lowering the validated LOQ [32]. The variation of T-S and E-S biomarkers due to 
samples without measurable MS signals, will be more difficult to be reduced, since the current 
used MS technology is of high mass accuracy and sensitivity. The intra-individual athlete 
baseline or after doping application variation of EAAS-S has to be defined in clinical studies. 
The inter-athlete population variation will play an important role and it has to be determined and 







































































The technological progress on MS instruments during the last decade and their uses for ITP 
analysis, in particular the high-resolution LC/MS, it has improved the sensitivity and specificity 
of the analytes detection. The improvement in the sensitivity resulted in the detection of the 
analytes in full scan MS acquisition mode and, subsequently, resulted in the increase of the 
detected analytes in a single run for both positive and negative ionizations. The latter proved the 
feasibility of measurement of a number of intact sulfate Phase II EAAS-S. The present study 
used the recent MS instrumental improvements to create males and females athlete population 
reference ranges for EAAS and EAAS-S concentrations. Several ratios from the WADA GC/MS 
and LCMS ITP have also been presented. The study created unbiased and realistic statistics for 
the population. To support the unbiased statistics, samples with detected EAAS and EAAS-S 
below LOQ were not excluded from the studied population. On the contrary, samples were 
excluded from the population if one or more of the following criteria was met: samples reported 
as non-negative and samples characterized as not valid according to the WADA Technical 
Document [6] for EAAS analysis related to detection of confounding factors or microbial 
degradation. The new SP biomarkers, in the context of individual analyte concentrations or 
ratios, were described through their population statistics, like mean, median, confidence interval, 
reference limits, outliers. Those additional biomarkers may be useful to improve the detectability 
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Table 1. Statistics of the monitored steroids in a male (n=780) and a female (n=373) population including the inter-quartile range (IQ1–IQ3), the percentage 
of measurements below LOD and below LOQ, median, mean, minimum, maximum concentration and the number of outliers. 
Compounds  
 
 Male         
  LOD LOQ % ˂ LOD % ˂ LOQ 1Q1  Median  Mean IQ3 Min  Max # Outliers 








T 0.33 1.0 0.13 0.13 8.4 28 34 46 0.10 190 0 
E 0.33 1.0 - - 18 31 38 49 3.6 199 0 
A 6.7 20 - - 2124 3039 3374 4267 523 12868 1 
Etio 6.7 20 - - 1198 1772 1967 2454 217 6755 0 
5αAdiol 0.33 1.0 - - 30 48 59 77 5.4 543 2 
5βAdiol 0.33 1.0 - - 55 100 153 201 7.3 1258 0 
EAAS-S  
T-S 0.15 0.50 9.8 10 0.65 1.7 3.8 4.2 0.005 54 0 
E-S 0.15 0.50 - - 7.8 12 13.3 16.8 1.2 49 2 
A-S 3.0 10 - 0.27 295 539 736 1011 5.2 5566 0 
Etio-S 3.0 10 - 0.90 71 190 276 403 6.4 2349 0 
DHEA-S 3.0 10 - 0.13 141 395 1235 1186 9.7 39612 0 






Table 1. (Continued)  
Compounds    Female         
  LOD LOQ % ˂ LOD % ˂ LOQ 1Q1  Median  Mean IQ3 Min  Max # Outliers 
  (ng/mL) (ng/mL)   (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL) (ng/mL)   
EAAS 
T 0.33 1.0 3.2 14 1.7 4.6 6.9 9.6 0.05 78 0 
E 0.33 1.0 - 0.27 5.7 9.8 13 16 0.50 104 0 
A 6.7 20 - - 1056 1682 2030 2609 74 10275 0 
Etio 6.7 20 - - 889 1391 1654 2043 171 8982 0 
5αAdiol 0.33 1.0 - - 10 16 20 24 1.0 120 1 
5βAdiol 0.33 1.0 - - 15 33 62 79 3.6 999 0 
EAAS-S  
T-S 0.15 0.50 32 24 0.08 0.39 0.81 0.87 0.005 36.5 0 
E-S 0.15 0.50 1.6 4.3 1.4 2.6 4.5 4.4 0.005 364 0 
A-S 3.0 10 - 0.27 138 249 378 512 4.57 2208 0 
Etio-S 3.0 10 - - 109 249 312 425 10.16 2067 0 
DHEA-S 3.0 10 0.54 2.1 66 151 533 536 0.03 8730 0 





Table 2. Statistics of the monitored steroid ratios in male population including the inter-quartile 
range (IQ1–IQ3), median, mean, minimum, maximum concentration and the number of outliers. 
No. Ratios Male             
    IQ1  Median  Mean IQ3 Min  Max #Outliers 
1 T/E_TD 0.36 0.96 1.2 1.6 0.04 9.9 0 
2 T/E_Conc. 0.34 0.95 1.1 1.6 0.01 9.2 0 
3 A/T 66 107 268 321 16 14200 0 
4 A/Etio 1.3 1.8 1.9 2.3 0.39 5.6 3 
5 5αAdiol/5βAdiol 0.27 0.48 0.61 0.82 0.05 2.8 1 
6 5αAdiol/E 0.38 0.65 0.81 1.0 0.03 5.7 1 
7 A/E 62 98 128 163 13 864 0 
8 T/T-S 3.3 13 39 38 0.04 1892 0 
9 E/T-S 5.0 16 50 45 0.18 3603 0 
10 A/T-S 575 1501 4011 3791 54 120395 0 
11 Etio/T-S 366 884 2116 2204 24 61359 0 
12 5αAdiol/T-S 9.3 25 63 63 0.41 1959 0 
13 5βAdiol/T-S 19 56 155 147 0.91 6064 0 
14 A-S/T-S 118 268 611 648 2.2 24441 0 
15 Etio-S/T-S 31 91 304 253 0.67 10540 0 
16 epiA-S/T-S 26 58 103 121 0.79 1744 0 
17 T/E-S 0.99 2.4 3.1 4.1 0.02 19 0 
18 E/E-S 1.5 2.7 3.5 4.2 0.38 35 0 
19 A/E-S 171 256 318 384 41 1853 1 





Table 2. (Continued)  
No. Ratios Male             
    IQ1  Median  Mean IQ3 Min  Max #Outliers 
21 5αAdiol/E-S 2.5 4.1 5.5 7.0 0.38 45 0 
22 5βAdiol/E-S 4.6 9.5 14 18 0.59 107 0 
23 epiA-S/E-S 5.1 9.5 13 16 0.19 117 1 
24 A-S/E-S 25 49 62 82 0.779 446 0 
25 Etio-S/E-S 5.9 16 26 36 0.498 299 0 
26 T-S/E-S 0.09 0.16 0.27 0.34 0.003 2.5 0 
27 T/(E+E-S) 0.22 0.69 0.73 1.0 0.006 4.5 0 
28 epiA-S/E 1.5 3.7 6.6 8.0 0.03 191 0 
29 T/DHEA-S 0.01 0.05 0.21 0.21 0.0001 3.9 0 
30 E/DHEA-S 0.02 0.07 0.24 0.25 0.0003 5.2 0 
31 A/DHEA-S 2.6 7.5 19 22 0.16 297 0 
32 Etio/DHEA-S 1.5 4.7 11 12 0.08 143 0 
33 5αAdiol/DHEA-S 0.04 0.12 0.32 0.35 0.002 6.26 0 
34 5βAdiol/DHEA-S 0.07 0.27 0.81 0.83 0.003 15 0 
35 epiA-S/DHEA-S 0.13 0.24 0.33 0.45 0.02 2.4 0 
36 A-S/DHEA-S 0.57 1.2 2.1 2.6 0.08 29 0 







Table 3. Statistics of the monitored steroid ratios in female population including the inter-quartile 
range (IQ1–IQ3), median, mean, minimum, maximum concentration and the number of outliers. 
No. Ratios female             
    IQ1  Median  Mean IQ3 Min  Max #Outliers 
1 T/E_TD 0.18 0.53 0.76 1.1 0.02 8.5 0 
2 T/E_Conc. 0.16 0.50 0.75 1.1 0.005 8.6 0 
3 A/T 192 322 1064 804 27 16457 0 
4 A/Etio 0.90 1.2 1.4 1.6 0.39 5.0 1 
5 5αAdiol/5βAdiol 0.25 0.46 0.58 0.81 0.01 2.2 0 
6 5αAdiol/E 0.34 0.61 0.87 1.1 0.05 4.6 0 
7 A/E 104 177 230 306 14 1256 0 
8 T/T-S 2.5 7.0 20 20 0.08 319 0 
9 E/T-S 7.9 17 42 47 0.61 737 0 
10 A/T-S 1274 2899 7021 7419 49 68264 0 
11 Etio/T-S 1189 2391 5572 6102 25 73591 0 
12 5αAdiol/T-S 13 28 64 71 0.79 1095 0 
13 5βAdiol/T-S 27 67 158 152 1.5 2667 0 
14 A-S/T-S 230 507 1252 1348 16 21992 0 
15 Etio-S/T-S 147 448 1289 1106 3.1 27715 0 
16 epiA-S/T-S 32 76 170 201 1.4 2343 0 
17 T/E-S 0.63 2.0 3.2 3.5 0.01 91 0 
18 E/E-S 2.1 3.6 6.0 7.3 0.08 67 0 
19 A/E-S 376 667 1067 1087 1.1 15538 0 





Table 3. (Continued)  
No. Ratios Female             
    IQ1  Median  Mean IQ3 Min  Max #Outliers 
21 5αAdiol/E-S 3.4 5.7 11 11 0.02 222 0 
22 5βAdiol/E-S 6.2 14 29 33 0.07 466 0 
23 epiA-S/E-S 7.6 14 25 30 0.03 208 0 
24 A-S/E-S 53 105 174 208 0.414 1887 0 
25 Etio-S/E-S 40 90 170 182 0.072 4375 0 
26 T-S/E-S 0.09 0.20 0.44 0.44 0.01 14 0 
27 T/(E+E-S) 0.12 0.39 0.52 0.75 0.004 5.3 0 
28 epiA-S/E 1.7 3.7 7.3 9.2 0.12 78 0 
29 T/DHEA-S 0.01 0.02 0.16 0.08 0.00004 26 0 
30 E/DHEA-S 0.02 0.06 0.56 0.16 0.001 143 0 
31 A/DHEA-S 3.4 10 32 27 0.20 2807 0 
32 Etio/DHEA-S 2.6 8.1 37 23 0.20 6356 0 
33 5αAdiol/DHEA-S 0.03 0.09 0.62 0.26 0.001 127 0 
34 5βAdiol/DHEA-S 0.07 0.20 1.9 0.60 0.002 471 0 
35 epiA-S/DHEA-S 0.11 0.21 0.62 0.37 0.02 121 0 
36 A-S/DHEA-S 0.64 1.4 7.3 3.1 0.08 1748 0 







Table 4. The 97.5%, 99%, 99.5% reference limits (RL) and the respective 95% confidence intervals (CI) 
of all compounds for male population and female population. 
Compounds  Male           
  97.5% RL 95%CI 99 % RL 95% CI 99.5% RL 95%CI 
EAAS 
     
  
T 113 102-128 138 123-152 152 135-190 
E 115 105-129 151 123-159 158 138-181 
A 7408 7077-8106 8378 7747-9567 9554 8242-12868 
Etio 4616 4212-5160 5503 4882-5824 5780 5319-6254 
5αAdiol 162 145-187 214 176-270 270 206-543 
5βAdiol 584 507-672 747 644-911 880 737-1135 
EAAS-S 
     
  
T-S 19 17-23 26 23-34 33 25-43 
E-S 34 31-38 41 35-44 44 41-49 
A-S 2528 2166-2703 3166 2691-3562 3558 2865-4085 
Etio-S 1037 904-1128 1213 1051-1530 1435 1136-2067 
DHEA-S 8706 6606-10462 11588 9223-15396 15314 11244-18166 
epiA-S 595 537-654 781 633-916 897 733-1356 
Compounds  Female           
  97.5% RL 95%CI 99 % RL 95% CI 99.5% RL 95%CI 
EAAS 
     
  
T 29 21-39 39 29-52 48 37-78 
E 38 34-73 79 45-97 95 67-104 
A 5904 4707-6432 7321 6367-9458 9171 6916-10275 
Etio 4940 3767-5998 6350 5117-8685 8633 5998-8982 
5αAdiol 70 61-80 81 72-97 91 78-120 
5βAdiol 272 203-401 463 298-646 584 395-999 
EAAS-S 
     
  
T-S 4.3 2.8-7.6 8.50 5.0-19 16 6.2-37 
E-S 15 9.5-17 29.0 16 -124 74 19-364 
A-S 1443 1222-1862 1885 1490-2024 1974 1862-2208 
Etio-S 1040 905-1128 1213 1051-1530 1435 1131-2067 
DHEA-S 3562 2628-5386 6610 3834-7709 7529 5181-8730 





Table 5. The 97.5%, 99%, 99.5% reference limits (RL) and the respective 95% confidence intervals (CI) of 
all steroid ratios for male population. 
No. Ratio Male           
    97.5% RL 95%CI 
99 % 
RL 95% CI 
99.5% 
RL 95%CI 
1 T/E_TD 3.5 3.2-3.7 3.9 3.5-4.8 4.6 3.8-6.7 
2 T/E_Conc. 3.4 3.1-3.65 3.8 3.5-4.7 4.5 3.7-6.7 
3 A/T 1093 968-1229 1380 1207-1816 1829 1316-3281 
4 A/Etio 3.8 3.5-4.3 4.8 4.2-5.3 5.3 4.7-5.4 
5 5αAdiol/5βAdiol 1.7 1.6-2.0 2.1 1.9-2.2 2.2 2.0-2.8 
6 5αAdiol/E 2.6 2.2-3.0 3.3 2.7-4.5 4.6 3.2-5.7 
7 A/E 400 341-447 543 418-630 630 526-863 
8 T/T-S 245 191-344 410 299-686 653 375-1383 
9 E/T-S 308 248-374 500 338-720 698 479-1940 
10 A/T-S 21778 18903-27211 39992 24747-83654 69791 36744-108539 
11 Etio/T-S 10643 8701-14978 17093 13547-35349 32879 16784-59931 
12 5αAdiol/T-S 359 284-426 542 383-880 778 520-1922 
13 5βAdiol/T-S 853 642-1264 1862 1054-3314 2687 1527-5407 
14 A-S/T-S 2972 2426-3588 5321 3231-7157 7183 5096-22449 
15 Etio-S/T-S 2224 1527-2753 3253 2315-4881 4918 3163-9347 
16 epiA-S/T-S 462 406-542 780 530-1239 1233 606-1713 
17 T/E-S 11 9.3-12 13 12-16 16 13-18 
18 E/E-S 12 10-13 16 12-19 19 14-21 
19 A/E-S 1006 859-1143 1188 1075-1455 1459 1162-1615 








No. Ratio Male           




RL 95% CI 
99.5% 
RL 95%CI 
21 5αAdiol/E-S 18 17-23 25 21-40 30 24-34 
22 5βAdiol/E-S 50 43-56 61 54-71 70 58-107 
23 epiA-S/E-S 44 39-51 55 51-67 67 55-83 
24 A_S/E_S 193 179-203 236 202-320 320 228-421 
25 Etio_S/E_S 95 86-119 141 115-170 169 138-299 
26 T-S/E-S 1.2 0.97-1.5 1.6 1.3-2.1 2.1 1.5-2.4 
27 T/(E+E-S) 2.0 1.8-2.2 2.3 2.2-2.5 2.5 2.3-4.5 
28 epiA-S/E 31 26-36 45 35-54 54 45-83 
29 T/DHEA-S 1.4 1.1-1.8 1.8 1.6-2.3 2.3 1.8-3.7 
30 E/DHEA-S 1.5 1.2-1.9 2.3 1.8-3.4 3.2 2.2-5.0 
31 A/DHEA-S 112 90-125 148 119-190 189 143-254 
32 Etio/DHEA-S 60 51-69 80 64-119 119 76-136 
33 5αAdiol/DHEA-S 1.8 1.6-2.2 2.7 2.1-3.9 3.9 2.4-5.6 
34 5βAdiol/DHEA-S 5.1 4.2-7.0 7.7 5.8-9.7 9.5 7.5-12.9 
35 epiA-S/DHEA-S 1.1 1.0-1.3 1.4 1.2-1.7 1.7 1.4-2.0 
36 A-S/DHEA-S 8.8 7.5-10 12 10-15 16 12-23 






Table 6. The 97.5%, 99%, 99.5% reference limits (RL) and the respective 95% confidence intervals (CI) of 
all steroid ratios for female population. 
No. Ratio Female           
    97.5% RL 95%CI 
99 % 
RL 95% CI 
99.5% 
RL 95%CI 
1 T/E_TD 2.9 2.3-3.1 3.2 2.9-5.6 4.6 3.1-8.5 
2 T/E_Conc. 2.7 2.4-3.2 3.7 2.8-5.5 5.0 3.2-8.6 
3 A/T 6867 5646-8783 12920 6998-15453 15100 8545-16457 
4 A/Etio 3.1 2.7-3.9 4.1 3.2-5.0 4.7 3.6-5.0 
5 5αAdiol/5βAdiol 1.7 1.5-1.8 1.9 1.7-2.1 2.1 1.8-2.2 
6 5αAdiol/E 3.1 2.7-3.7 3.9 3.2-4.3 4.2 3.5-4.6 
7 A/E 740 614-830 887 766-1244 1242 828-1256 
8 T/T-S 125 90 -200 213 130-319 318 158-319 
9 E/T-S 245 160-301 367 255-737 557 285-737 
10 A/T-S 43487 28512-60237 62180 43713-68264 65373 52725-68264 
11 Etio/T-S 37733 24307-46500 46882 36562-73591 61700 44250-73591 
12 5αAdiol/T-S 357 259-584 589 360-1095 852 409-1095 
13 5βAdiol/T-S 1070 721-1655 1926 1137-2667 2315 1191-2667 
14 A-S/T-S 8169 4815-11740 13697 7753-21992 18052 9895-21992 
15 Etio-S/T-S 9124 5896-14274 15286 8661-27715 21811 12545-27715 
16 epiA-S/T-S 971 650-1523 1659 943-2343 2105 1253-2343 
17 T/E-S 15 12-20 24 16-50 34 20-91 
18 E/E-S 27 18-29 45 27-64 63 31-67 
19 A/E-S 4215 3709-6400 10595 4284-14482 14267 6161-15538 








No. Ratio Female           




RL 95% CI 
99.5% 
RL 95%CI 
21 5αAdiol/E-S 53 43-74 79 53-134 100 77-222 
22 5βAdiol/E-S 158 104-220 278 165-466 454 207-466 
23 epiA-S/E-S 120 96-148 163 123-182 175 146-208 
24 A_S/E_S 829 560-958 1452 874-1809 1778 1022-1887 
25 Etio_S/E_S 804 523-1044 1402 853-3266 2791 1040-4375 
26 T-S/E-S 2.6 1.6-4.0 4.3 2.6-14 9.3 3.1-14 
27 T/(E+E-S) 1.7 1.4-2.2 2.4 1.8-3.6 3.2 2.2-5.3 
28 epiA-S/E 33 26-44 49 33-78 62 41-78 
29 T/DHEA-S 0.59 0.33-0.84 1.5 0.63-11 8.4 0.87-26 
30 E/DHEA-S 1.2 0.87-2.3 3.3 1.3-41 23 2.4-143 
31 A/DHEA-S 177 98-261 292 196-1087 785 247-2807 
32 Etio/DHEA-S 122 81-193 266 136-6356 1174 162-6356 
33 5αAdiol/DHEA-S 2.1 0.94-4.3 5.0 2.2-40 25 3.6-127 
34 5βAdiol/DHEA-S 3.6 2.4-9.0 9.1 4.0-148 69 7.3-471 
35 epiA-S/DHEA-S 1.0 0.80-1.7 1.9 1.2-36 17.8 1.7-121 
36 A-S/DHEA-S 12 8.6-25 28 13-513 259 22-1748 






Table 7. A calculated tentative upper limit of monitored steroids concentrations and ratios in a male 
and a female population 
Parameter Male population Female population 
   ( Far outside)x2 # Samples above 
upper limit 
(Far outside)x2 # Samples above 
upper limit 
T 320 0 66 1 
E 283 0 96 1 
A 21391 0 14537 0 
Etio 12443 0 11009 0 
5αAdiol 435 1 135 0 
5βAdiol 1277 0 539 1 
T-S 30 6 6.5 4 
E-S 88 0 27 4 
A-S 6320 0 3264 0 
Etio-S 2805 0 2747 0 
DHEA-S 8646 17 3891 7 
epiA-S 1394 1 568 0 
T/E_TD 11 0 7.8 1 
T/E_Conc. 11 0 8.2 1 
A/T 2174 1 5284 17 
A/Etio 11 0 7.8 0 
5αAdiol/5βAdiol 5.0 0 5.0 0 
5αAdiol/E 5.9 0 6.7 0 
A/E 928 0 1819 0 
T/T-S 285 15 146 4 
E/T-S 333 14 330 3 
A/T-S 26880 11 51709 4 
Etio/T-S 15433 10 41684 5 
5αAdiol/T-S 448 10 486 4 
5βAdiol/T-S 1064 14 1056 4 
A-S/T-S 4474 9 9405 5 
Etio-S/T-S 1835 25 7966 8 
epiA-S/T-S 807 7 1419 5 
T/E-S 27 0 24 3 
E/E-S 25 1 46 3 
A/E-S 2050 0 6439 4 






Table 7. (Continued)  
Parameter Male population Female population 
   ( Far outside)x2 # Samples above 
upper limit 
 ( Far outside)x2 # Samples above 
upper limit 
5αAdiol/E-S 40 1 70 5 
5βAdiol/E-S 114 0 229 4 
epiA-S/E-S 99 1 197 1 
A-S/E-S 506 0 1346 4 
Etio-S/E-S 253 1 1216 3 
T-S/E-S 2.2 2 3.0 4 
T/(E+E-S) 7.0 0 5.3 0 
epiA-S/E 55 3 64 1 
T/DHEA-S 1.6 14 0.57 9 
E/DHEA-S 1.8 14 1.2 10 
A/DHEA-S 159 6 197 8 
Etio/DHEA-S 88 7 169 5 
5αAdiol/DHEA-S 2.5 8 1.9 9 
5βAdiol/DHEA-S 6.2 14 4.4 7 
epiA-S/DHEA-S 2.8 0 2.3 2 
A-S/DHEA-S 17 2 21 5 
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